ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2019 and some content may be unavailable. To unlock all content for 2019, please visit the archives.

Abstract: SA-PO189

Rate and Predictors of Developing Monoclonal Gammopathy of Renal Significance (MGRS) Lesion on Renal Biopsy in Patients with Positive Monoclonal Studies

Session Information

  • Onco-Nephrology: Clinical
    November 09, 2019 | Location: Exhibit Hall, Walter E. Washington Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Onco-Nephrology

  • 1500 Onco-Nephrology

Authors

  • Klomjit, Nattawat, Mayo Clinic, Rochester, Minnesota, United States
  • Leung, Nelson, Mayo Clinic, Rochester, Minnesota, United States
  • Fervenza, Fernando C., Mayo Clinic, Rochester, Minnesota, United States
  • Sethi, Sanjeev, Mayo Clinic, Rochester, Minnesota, United States
  • Zand, Ladan, Mayo Clinic, Rochester, Minnesota, United States
Background

Monoclonal gammopathy (MG) can cause renal damage in a subset of patients known as MGRS. However, the rate of finding an MGRS lesion on a biopsy in a patient with MG and the clinical factors that would predict the likelihood of finding such lesions remains unknown

Methods

We identified all patients that had a positive serum MG based on a positive serum electrophoresis or immunofixation between 2013 through 2018 at the Mayo Clinic Rochester. We then excluded those patients who had a diagnosis of multiple myeloma, amyloidosis, or those with a renal transplant.

Results

We identified 4257 patients who met the inclusion criteria, of which 105 had a renal biopsy (2.47%). Of the 105 patients, 25 (23.8%) had an MGRS lesions. The most common MGRS lesions included proliferative glomerulonephritis with monoclonal immunoglobulin deposition (PGNMID) (n=10, 40%) followed by cryoglobulinemic vasculitis (n=5, 20%). In the remaining 80 patients, the most common lesions included arteriosclerosis (n=19, 23.75%), diabetic nephropathy (n=14, 17.5%), ANCA associated vasculitis (n=8, 8.8%) and IgAN (n=8, 8.8%). At the time of renal biopsy, there were no differences in age, sex, serum creatinine, hemoglobin and type of light chain between 2 groups. Compared to non-MGRS patients, MGRS patients had a significantly higher systolic blood pressure (p= 0.03) and more likely to have IgG heavy chain (p =0.05). Hematuria at time of the renal biopsy was the most significant predictor of finding an MGRS lesion with an OR of 6.21 (2.1-18.3, p=0.0003), followed by proteinuria >3.5 g/d with OR of 2.61 (1.01-6.7, p=0.04), and an elevated ratio of affected/unaffected light chain (OR= 1.08, 1.0-1.16, p=0.0001). Having a combination of hematuria and proteinuria≥2 g/day was also highly predictive with an OR of 5.67 (2.0-16.1, P=0.001).

Conclusion

Among patient with a positive MG who had a renal biopsy in the absence of amyloidosis, 75% had a lesion unrelated to the MG with arteriosclerosis and DN being the most common findings. Hematuria, nephrotic range proteinuria or high risk features (hematuria+proteinuria≥2 g) were the strongest predictors of finding an MGRS lesion.